Key terms
About SVRA
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SVRA news
Apr 12
4:23pm ET
Savara Inc. Experiences Board Changes and Governance Shifts
Apr 09
8:05am ET
Optimistic Buy Rating for Savara Based on Molgramostim’s Market Potential and Study Outcomes
Mar 11
6:26am ET
Buy Rating Affirmed: Anticipating IMPALA-2 Trial Success and aPAP Treatment Breakthrough with Molgramostim
Mar 08
7:47am ET
Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)
Mar 08
12:25am ET
Optimistic Buy Rating for Savara on Molgramostim’s Market Potential and Strong Financials
Mar 07
4:13pm ET
Savara reports Q4 EPS (9c), consensus (10c)
Mar 07
10:29am ET
Biotech Alert: Searches spiking for these stocks today
Mar 04
7:31am ET
Savara price target raised to $16 from $7 at Piper Sandler
Feb 29
7:48am ET
Piper Sandler Keeps Their Buy Rating on Savara (SVRA)
Feb 27
5:55am ET
Savara management to meet with Piper Sandler
Feb 26
4:55am ET
Savara management to meet with Piper Sandler
Feb 23
8:03am ET
Savara management to meet with Piper Sandler
Feb 22
8:21am ET
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Harmony Biosciences Holdings (HRMY) and Tandem Diabetes Care (TNDM)
Feb 21
4:55am ET
Savara management to meet virtually with Piper Sandler
Feb 20
8:16am ET
Savara management to meet virtually with Piper Sandler
Feb 16
8:42am ET
Savara Partners with Fujifilm for Molgramostim Development
Feb 15
4:44am ET
Savara initiated with an Outperform at JMP Securities
Feb 15
1:34am ET
Analysts’ Top Healthcare Picks: Savara (SVRA), Bruker (BRKR)
Jan 30
12:49am ET
3 Best Stocks to Buy Now, 1/30/2024, According to Top Analysts
Jan 26
11:25am ET
Biotech Alert: Searches spiking for these stocks today
Jan 26
4:32am ET
Savara Sets Executive Bonus Targets for Fiscal 2024
No recent press releases are available for SVRA
SVRA Financials
Key terms
Ad Feedback
SVRA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SVRA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
